Public Title	Aplidin in relapsed/refractory ALL
Scientific Title	A Phase II multicenter, open-label, clinical and pharmacokinetic study of Aplidin ® (APLD) as a 1-hour weekly IV infusion, in patients with relapsed or refractory acute lymphoblastic leukemia (ALL)
Short Title	ALL Aplidin
Id KN/ELN	LN_GMALLE_2005_53
Trialgoup	GMALL
Type of Trial	multicentric
Phase	Phase II
Disease	Acute lymphoblastic leukemia(ALL) All subtypes
Stage of Disease	relapsed/refractory

Inclusion Criteria

- Written informed consent
- Underlying disease: ALL in >=1st relapse or refractory
- if 1st relapse: time from first treatment to relapse has to be <18 months
- if >1st relapse: all patients are eligible
- Site of relapse has to include bone marrow ± extramedullary relapse (e.g.CNS, testicular)
- Previous line(s) of systemic chemotherapy should have been finished at least 3 weeks before patient registration
- Prior radiotherapy is allowed.
- Prior auto and/ or allo SCT is allowed.
- In case of allo SCT, patient has to be off immunosuppressive agents
- Recovery from any toxicity derived from previous treatments.
- The presence of alopecia and NCI-CTC grade < 2 symptomatic peripheral neuropathy is allowed.
- Age > 18 years.
- Performance status (ECOG) < 2
- Adequate renal and hepatic function
- Creatinine clearance > 40 ml/min (Cockcroft and Gault formula)
- Serum bilirubin 1.5 mg/dL and alkaline phosphatase 2.5 x ULN
- AST, ALT < 2.5 x ULN
- Albumin > 25 g/L
- Left ventricular ejection fraction within normal limits.

Exclusion Criteria

- Prior therapy with APLD
- Wash-out periods since the end of the precedent therapy less than:
- 6 weeks for nitroso-urea or high dose chemotherapy
- 3 weeks for other chemotherapies or biological agents
- 4 weeks for radiation or radionuclide therapy
- 30 days for any investigational product
- 2 weeks for immunosuppressive therapy after allo SCT
- Pregnant or lactating women
- Men and women of reproductive potential who are not using effective contraceptive methods (details see protocol)
- History of another neoplastic disease. The exceptions are:
- non-melanoma skin cancer

- carcinoma in situ of any site
- any other cancers curatively treated and no evidence of disease for at least 5 years.
- Other relevant diseases or adverse clinical conditions:
- Congestive heart failure or angina pectoris, myocardial infarction
- Uncontrolled arterial hypertension
- Uncontrolled cardiac supraventricular arrhythmias
- Cardiac ventricular arrhythmia
- History of significant neurological or psychiatric disorders
- Active severe infection
- Infection by HIV, HBV or HCV
- Myopathy or any clinical situation that causes significant and persistent elevation of CK (>2.5 ULN in two different determinations performed with one week apart)
- Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis)
- Limitation of the patient's ability to comply with the treatment or follow-up protocol.
- Uncontrolled endocrine diseases (e.g. diabetes mellitus, hypothyroidism or hyperthyroidism)
- Treatment with any investigational product in the 30 days period before inclusion in the study.
- Known hypersensitivity to Aplidin, mannitol, cremophor EL, or ethanol

Age	>= 18 years
Status	Closed
start of Recruitment	24.10.2005
Recruiting countries	Germany
Leader	Junghanß, Prof. Dr., Christian Medizinische Klinik.Hämatologie/Onkologie Ernst-Heydemannstr. 6 18057 Rostock Tel: +49 (0)381 494 7421 Fax: +49 (0)381 494 7422 Email: christian.junghanss@med.uni-rostock.de
Scientific Contact (WHO)	Junghanß, Prof. Dr., Christian Medizinische Klinik.Hämatologie/Onkologie Ernst-Heydemannstr. 6 18057 Rostock Tel: +49 (0)381 494 7421 Fax: +49 (0)381 494 7422 Email: christian.junghanss@med.uni-rostock.de
Contact Person	**principal investigator** Junghanß, Prof. Dr., Christian Tel: +49 (0)381 494 7421 Fax: +49 (0)381 494 7422 Email: christian.junghanss@med.uni-rostock.de
Centre of Trial	Universitätsklinikum Rostock
Sponsors	Pharma Mar, S.A. (Main Sponsor)

Supporters

Pharma Mar, S.A.
Avda de los Reyes,1
28770 Madrid
Tel: +34 (0)91 846 6000
Fax: +34 (0)91 846 6003
Homepage: www.pharmamar.com

Interventions

- Aplidin : 1-hour weekly IV infusion

Therapy

During the Treatment Period, all patients are to attend study center visits on day 1,8,15 and 22 of every 28-day cycle. Patients will receive APLD only on day 1,8 and 15 of each cycle. Visit at day 22 must be performed in order to evaluate toxicity and adverse events. Treatment period will continue until disease progression, significant increase in ALL-related symptoms, unmanageable toxicity, withdrawal of patient's consent or treatment delay>2 weeks (except in case of obvious patient's clinical benefit).